A one-minute look back at the week of January 19, 2015, in managed care, including Marilyn Tavenner's departure from CMS and oncology drug pricing.
The top story in managed care this week was the news that Marilyn Tavenner would be resigning from her post as chief of CMS at the end of February. Andy Slavitt is slated to take over temporarily until Senate approves his appointment or another candidate is confirmed.
Although clinical trial results for Kite Pharma’s cancer immuno-therapy aren’t due until 2016, the company learned its lesson from last year’s price wars over Gilead’s hepatitis C treatment.
Lastly, we invite you to take a look at this month’s The American Journal of Managed Care as we kick off our 20th year of publication with a special commentary by co-editors-in-chief, A. Mark Fendrick, MD, and Michael E. Chernew, PhD.